Ro Pricing Analysis: What You Actually Pay for Telehealth Weight Loss, ED, and Hair Loss Treatment

How Ro Structures Its Pricing

Ro operates a subscription-based direct-to-consumer model where the consultation fee is folded into the monthly price. You pay one recurring charge that covers the provider visit, medication, and shipping. That sounds simple. The reality is more layered.

Consultation and Platform Fees

Ro does not charge a separate consultation fee for most programs. The provider evaluation is asynchronous, meaning you fill out a health questionnaire and a licensed clinician reviews it without a live video call. This keeps overhead low and allows Ro to bundle the visit cost into the medication price. For patients accustomed to $50 to $75 telehealth copays, the bundled model can feel like a discount. But the medication markup compensates for the "free" visit.

Subscription Tiers and Dose Escalation

Most Ro programs use tiered pricing. The GLP-1 weight loss program, for example, starts at a lower monthly rate during the initial titration phase and increases as the dose climbs. A patient starting compounded semaglutide at 0.25 mg weekly may pay $149/month, but the cost rises to $249 or $299/month at maintenance doses of 1.7 mg or 2.4 mg 1. This tiered structure mirrors the dose-dependent manufacturing cost of compounded injectables, but patients who budget based on the introductory price often underestimate their 12-month spend.

What Insurance Covers (and Doesn't)

Ro does not accept insurance for most of its programs. The GLP-1 weight loss program uses compounded semaglutide, which is not an FDA-approved finished product and therefore falls outside formulary coverage. For branded medications like Wegovy, some insurers cover the drug itself, but Ro's platform fee remains out-of-pocket. The American Medical Association has noted that coverage gaps for anti-obesity medications affect roughly 40% of commercially insured adults 2.

GLP-1 Weight Loss Program: The Biggest Ticket Item

Ro's weight loss vertical is its fastest-growing revenue line and its most expensive offering for patients. The program centers on compounded semaglutide injections, prescribed after an online evaluation.

Monthly Cost Breakdown

At the time of this analysis, Ro's GLP-1 program costs between $149 and $299 per month. The lower figure applies during the first 4 to 8 weeks of titration at 0.25 mg weekly. As the dose increases through 0.5 mg, 1.0 mg, and toward the 2.4 mg target used in the STEP-1 trial (N=1,961), the monthly cost escalates 1. STEP-1 demonstrated 14.9% mean body weight reduction at 68 weeks with semaglutide 2.4 mg versus 2.4% with placebo.

A realistic 12-month projection looks like this:

| Phase | Duration | Monthly Cost | Subtotal | |---|---|---|---| | Titration (0.25 to 0.5 mg) | Months 1 to 2 | $149 | $298 | | Mid-dose (1.0 to 1.7 mg) | Months 3 to 5 | $199 to $249 | $597 to $747 | | Maintenance (1.7 to 2.4 mg) | Months 6 to 12 | $249 to $299 | $1,743 to $2,093 | | Estimated Year 1 Total | | | $2,638 to $3,138 |

Lab Work and Monitoring Costs

Ro requires baseline labs before prescribing GLP-1 medications. These typically include a comprehensive metabolic panel, HbA1c, lipid panel, and thyroid function tests. Ro does not perform these labs in-house. Patients must visit a local lab (Quest, Labcorp, or a primary care provider), and costs range from $0 with insurance to $150+ out-of-pocket. The Endocrine Society recommends metabolic screening before initiating GLP-1 receptor agonist therapy, including fasting glucose and renal function 3.

Compounded vs. Branded Semaglutide

Ro primarily dispenses compounded semaglutide, not branded Wegovy. This distinction matters. Compounded drugs are prepared by pharmacies under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act and are not individually evaluated by the FDA for safety or efficacy 4. The FDA has issued multiple warnings about compounded semaglutide products, including concerns about dosing accuracy and sterility. Branded Wegovy carries a wholesale acquisition cost of roughly $1,349/month, which explains the market demand for compounded alternatives. But patients should understand the regulatory trade-off.

Erectile Dysfunction Treatment Costs

Ro's original product line was Roman, focused on ED. Pricing here is significantly lower than the GLP-1 program and more competitive with pharmacy alternatives.

Generic Sildenafil and Tadalafil

Generic sildenafil through Ro costs approximately $2 to $6 per dose, depending on quantity ordered. A 30-tablet supply of sildenafil 20 mg (prescribed off-label for ED at doses of 40 to 100 mg) runs roughly $60 to $120/month. Generic tadalafil (the active ingredient in Cialis) costs $4 to $11 per dose. Daily low-dose tadalafil 5 mg, which has demonstrated efficacy for both ED and lower urinary tract symptoms in a meta-analysis of 11 RCTs (N=3,243), runs approximately $120 to $150/month through Ro 5.

How This Compares to GoodRx and Retail Pharmacy

A critical comparison point: generic sildenafil 20 mg is available at retail pharmacies for as little as $0.30 to $1.00 per tablet with a GoodRx coupon. Ro's per-dose pricing is 2x to 6x higher than the cheapest retail option. The premium buys convenience (no in-person visit, home delivery) and bundled clinical oversight. Whether that premium is worth it depends on whether a patient already has a prescribing relationship with a physician.

Brand-Name Options

Ro also offers brand-name Viagra and Cialis at market price, though few patients choose these given the cost differential. Brand Viagra runs $70+ per pill at retail. Ro does not meaningfully discount branded ED medications.

Hair Loss Treatment Pricing

Ro's hair loss program (originally under the Keeps sub-brand, now integrated) centers on finasteride and minoxidil.

Finasteride

Oral finasteride 1 mg daily costs $12 to $20/month through Ro. Retail pharmacy pricing with a coupon is comparable ($3 to $15/month), so Ro's margin here is thinner. A 5-year Japanese study (N=3,177) and the original Kaufman trial (N=1,553) established that finasteride 1 mg increased hair count by 7 to 11% over 12 months and maintained results through 5 years in most men 6.

Topical Combinations

Ro offers compounded topical finasteride/minoxidil combinations at $30 to $50/month. These are not FDA-approved combination products. The rationale is dual-mechanism coverage (5-alpha reductase inhibition plus vasodilation), and a 2022 randomized trial (N=458) found topical finasteride 0.25% non-inferior to oral finasteride 1 mg for vertex hair count at 24 weeks with lower systemic exposure 7.

Mental Health Services and Other Programs

Ro expanded into mental health with anxiety and depression treatment. Pricing runs $20 to $75/month depending on the medication.

What's Included

The mental health program covers an asynchronous provider evaluation, a prescription for an SSRI or SNRI if appropriate, and ongoing messaging access to the prescriber. Generic sertraline or escitalopram through Ro costs $20 to $30/month. Retail pricing for these same generics is often under $10/month with a coupon, making Ro's premium entirely attributable to the platform and provider access.

Limitations

Ro does not offer therapy, psychiatric evaluation for complex conditions, or controlled substance prescriptions (no benzodiazepines or stimulants). The American Psychiatric Association guidelines recommend combined pharmacotherapy and psychotherapy for moderate-to-severe depression 8. Patients using Ro's mental health program as a standalone treatment for moderate depression may be receiving incomplete care.

Hidden Costs and Total First-Year Spend

The advertised monthly price is not the full picture. Several costs sit outside the subscription.

Lab Work

Required for GLP-1 and sometimes for other programs. Budget $50 to $200 annually if paying out-of-pocket.

Dose Changes and Restarts

If a patient pauses their GLP-1 program and restarts, Ro may require a new evaluation period at the lower dose tier, extending time at subtherapeutic doses and adding months of payment before reaching maintenance.

Shipping

Ro includes free standard shipping. Expedited shipping, when available, costs extra.

Opportunity Cost of No Insurance Billing

Because Ro does not bill insurance for most services, patients cannot apply these costs toward their deductible or out-of-pocket maximum. For a patient spending $3,000/year on Ro's GLP-1 program, that is $3,000 that does not count toward their plan's $4,000 out-of-pocket max. This hidden cost matters most for patients who would otherwise meet their deductible through other medical expenses.

How Ro Compares to Competitors

The direct-to-consumer telehealth market includes Hims & Hers, Calibrate, Found, Henry Meds, and PlushCare, among others.

Ro vs. Hims for ED and Hair Loss

Hims prices generic sildenafil at $2 to $4/dose, comparable to Ro. Finasteride runs $12 to $16/month through Hims. The platforms are nearly identical in pricing for these categories. Differentiation comes down to user experience and provider responsiveness. Neither company publishes patient satisfaction data from validated instruments like the IIEF-5 9.

Ro vs. Calibrate and Found for Weight Loss

Calibrate charges approximately $135 to $199/month for its metabolic health program but requires patients to obtain GLP-1 medications separately through insurance or retail pharmacy. Found prices its program at $99 to $199/month with medication included. Ro sits in the middle-to-upper range for combined program-plus-medication pricing. The SURMOUNT-1 trial (N=2,539) showed tirzepatide produced 20.9% weight loss at 72 weeks at the 15 mg dose 10. Platforms offering tirzepatide (compounded or branded) may provide different value propositions than semaglutide-only programs.

When Ro Is the Better Value

Ro is most cost-effective for patients who want a single platform managing multiple conditions. A patient using Ro for ED treatment ($60/month) and hair loss ($15/month) pays roughly $75/month total with one login and one provider relationship. Splitting these across two platforms or a primary care provider plus retail pharmacy could cost less in raw dollars but adds coordination burden.

Is Ro Legit? Safety and Regulatory Standing

Ro is a licensed telehealth platform operating in all 50 states. Its providers are board-certified or board-eligible physicians and nurse practitioners licensed in the patient's state.

Regulatory Concerns

The primary regulatory question centers on compounded medications. The FDA has stated that compounded drugs "are not FDA-approved" and that patients "may be at greater risk" from compounded products versus commercially manufactured alternatives 4. Ro partners with 503B outsourcing facilities, which are subject to FDA inspection but receive less oversight than conventional pharmaceutical manufacturers.

Clinical Oversight Model

Ro's asynchronous model means most patients never speak with their provider in real time. The clinician reviews a questionnaire, orders labs if needed, and prescribes. Follow-up occurs through messaging. The American Telemedicine Association's practice guidelines support asynchronous evaluation for straightforward clinical scenarios but recommend synchronous (live) encounters for complex medical decision-making 11.

Patient Reviews

Ro holds a 4.0 to 4.3 rating on Trustpilot based on thousands of reviews. Common positive themes include fast shipping and easy onboarding. Common complaints center on difficulty reaching providers, automatic billing after cancellation attempts, and limited clinical follow-up. The absence of published patient-reported outcome data using validated measures (PHQ-9 for depression, IWQOL-Lite for weight-related quality of life) makes it difficult to assess clinical effectiveness beyond anecdotal reports.

Who Should and Shouldn't Use Ro

Ro works best for patients with straightforward, guideline-concordant conditions who prioritize convenience over cost minimization. A 35-year-old man with situational ED who wants sildenafil without an office visit is Ro's ideal customer. A patient with a BMI of 38, type 2 diabetes, and obstructive sleep apnea who needs GLP-1 therapy probably benefits more from an in-person obesity medicine specialist who can coordinate with their endocrinologist and bill insurance.

The CDC reports that 41.9% of U.S. Adults have obesity, and fewer than 2% of eligible patients receive anti-obesity pharmacotherapy 12. Platforms like Ro expand access. The question is whether expanded access at $3,000/year out-of-pocket actually reaches the populations with the highest burden, or primarily serves commercially attractive demographics already well-connected to care.

Patients considering Ro's GLP-1 program should request written confirmation of the compounding pharmacy's 503B registration status and most recent FDA inspection report before starting treatment.